Drug-price increases slow as benefits managers get tough
A new analysis shows attempts by drugmakers to raise prices are being wiped out in negotiations with managers of drug insurance benefits like Express Scripts Holding Co. and CVS Health Corp.
Eli Lilly and Co.
Articles
Experimental osteoporosis drug bests Lilly’s Forteo in study
The experimental medicine, called romosozumab, showed better results than Eli Lilly and Co.’s Forteo after 12 months, Amgen and UCB said in a joint statement Wednesday.
Lilly wins patent ruling over blockbuster drug Alimta
Eli Lilly and Co. won a court ruling that will keep generic versions of the chemotherapy drug Alimta off the U.S. market until a patent expires in 2022.
Surprising heart study could bring Lilly $1B annually
Eli Lilly and Co. didn’t win approval for a new drug last week. But its latest study of an existing diabetes drug could create a blockbuster in its own right—adding as much as $1 billion a year to the coffers of the Indianapolis-based drugmaker.
Lilly shares jump after positive study of diabetes drug
Lilly’s stock had its biggest intraday gain since 2009 Thursday after it announced trial results that showed Jardiance lowered the risk of heart attacks, stroke and death in a large trial of adults with type 2 diabetes.
Indiana health care investments simmer while national market sizzles
Hoosier entrepreneurs in health care and life sciences attracted more than $31 million from investors during the first half of the year. But too few Indiana companies have developed their technology enough to attract venture capitalists or tap stock markets.
Eli Lilly wins first trial over antidepressant ‘brain zaps’
A jury found Lilly isn't liable for withdrawal symptoms experienced by a woman who quit the antidepressant Cymbalta. The verdict may give the drugmaker leverage in fending off more than 5,000 other lawsuits over the drug.
Lilly accused at trial of hiding Cymbalta ‘brain zap’ risk
The drugmaker faces as many as 5,000 cases claiming it downplayed Cymbalta’s withdrawal risks, which allegedly include electrical-shock sensations, vomiting and insomnia.
Lilly expands R&D outside Indy—again
State and city leaders spend millions each year to entice companies to move here and add jobs here. But for the second time in three months, Eli Lilly and Co. has shown that the biggest attraction to a company is talented workers.
Lilly, Anthem show high risk, high reward strategy can pay off
The CEOs of Eli Lilly and Anthem are being rewarded by investors for taking high-risk approaches to develop breakthrough drugs, make major acquisitions.
Indy’s top 11 acquisition deals, before Anthem-Cigna
Anthem’s $54 billion bid for rival insurer Cigna is twice the size of the next-largest acquisition in the Indianapolis area, which occurred nearly a decade ago.
Lilly posts lackluster profit but boosts full-year forecast
Eli Lilly and Co.’s profits plunged 18 percent in the second-quarter but still easily beat the lowered expectations of Wall Street analysts.
Alzheimer’s trials offer little certainty for investors, patients
Shares of Eli Lilly and Co. stagnated in Wednesday morning trading as investors and patients wished that the effects of solanezumab were more pronounced. Rival Biogen offered muddy results from its own Alzheimer’s drug.
Study shows Lilly’s Alzheimer’s drug has small but lasting benefit
New data released Wednesday morning suggest that Eli Lilly and Co.’s Alzheimer’s drug has a modest but lasting impact on the memory-sapping disease. But analysts worry the impact is too small to be meaningful.
Lilly faces moment of truth this week
The Indianapolis-based drugmaker on Wednesday will release new data from patients taking its Alzheimer’s drug that could show whether the drug has slowed the progression of their disease. That will show investors whether the 45 percent rise in Lilly’s stock price over the past year is justified.
Lilly partner Immunocore raises record $320 million
Immunocore Ltd., which this week achieved the biggest private fundraising by a European biotechnology firm in 10 years, plans to accelerate development of its cancer therapy using the money and seek expedited approval.
PROXY CORNER: Eli Lilly and Co.
Eli Lilly and Co., Lilly Corporate Center, Indianapolis, 46285 (www.lilly.com) discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
Clot risk in Lilly lung-cancer drug raises FDA concerns
The drug, known as necitumumab, improved patients’ overall chances of survival, yet people taking the medicine also experienced more risk, Food and Drug Administration staff said in a report Tuesday.
Indiana’s medical research ‘trade deficit’
Indiana's life sciences companies are spending four times more on medical research than the state's hospitals, doctors and univerities are receiving from such companies for research projects. That means Indiana is missing out on more than $80 million a year.
Resurgence of Eli Lilly is touching all corners of region
Central Indiana's economy is diverse, but Lilly is such a behemoth that its ups and downs reverberate statewide.